OncoCyte announces new publication on transplant rejection assay

Oncocyte (OCX) announced the publication of new and positive data regarding its proprietary blood-based transplant rejection assay. The publication, “Association of Blood Donor-derived Cell-free DNA Levels with Banff Scores and Histopathological Lesions in Kidney Allograft Biopsies: Results From an Observational Study,” is co-authored by Oncocyte’s Drs. Ekke Schuetz and Julia Beck, inventors of the technology. Findings from the study bode well on both a strategic level for Oncocyte as well as on a scientific level for the transplant industry. “There are only a few publications on the dynamics of dd-cfDNA in other common pathologies beyond rejection,” said Oncocyte Chief Science Officer Dr. Schuetz. “Our study aimed to assess both the absolute and relative values of dd-cfDNA in diverse histopathological patterns, the correlation of dd-cfDNA with Banff lesion scores, and the recently suggested Banff-based activity and chronicity indices in consecutive cases of kidney transplant recipients undergoing indication biopsies.”